<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482584</url>
  </required_header>
  <id_info>
    <org_study_id>DiaBOSA</org_study_id>
    <nct_id>NCT02482584</nct_id>
  </id_info>
  <brief_title>Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea</brief_title>
  <official_title>DiaBOSA: Impact of CPAP Treatment on Arterial Stiffness in Patients With Type 2 Diabetes and Newly Diagnosed Obstructive Sleep Apnoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordsjaellands Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to investigate the effects of three months' treatment with a&#xD;
      CPAP-device versus control group on change in arterial stiffness in type 2 diabetes (T2D)&#xD;
      patients with newly detected Obstructive Sleep Apnoea (OSA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Obstructive sleep apnoea (OSA) is a common disorder characterised by recurrent&#xD;
      episodes of apnoea or hypopnoea during sleep. OSA is associated with excessive daytime&#xD;
      sleepiness and linked to increased cardiovascular morbidity and mortality. OSA can be&#xD;
      alleviated with Continuous Positive Airway Pressure (CPAP) treatment.&#xD;
&#xD;
      Cardiovascular disease is the major cause of decreased life expectancy, morbidity and reduced&#xD;
      quality of life in patients with type 2 diabetes (T2D). Increased stiffness of the aorta has&#xD;
      been associated with increased cardiovascular morbidity and mortality in diabetic patients.&#xD;
&#xD;
      Previous studies have reported a much higher frequency of OSA in patients with obesity and&#xD;
      T2D compared with non-diabetic subjects, and found that OSA was associated with arterial&#xD;
      stiffness. However, whether CPAP treatment improves arterial stiffness and insulin&#xD;
      sensitivity in T2D patients remain to be elucidated.&#xD;
&#xD;
      Objective: To investigate the effects of three months' treatment with a CPAP-device versus&#xD;
      sham CPAP on change in arterial stiffness in T2D patients with newly detected OSA.&#xD;
&#xD;
      Design: Randomised, controlled, multicentre study of intervention with CPAP treatment versus&#xD;
      control group. The treatment period is three months with a subsequent 9 months open&#xD;
      extension.&#xD;
&#xD;
      Patient population: 70 patients with T2D and newly diagnosed OSA recruited from Department of&#xD;
      Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Department of&#xD;
      Endocrinology, Gentofte University Hospital, Department of Endocrinology and Internal&#xD;
      Medicine, Aarhus University Hospital Nørrebrogade and Department of Internal Medicine,&#xD;
      Silkeborg Sygehus.&#xD;
&#xD;
      Intervention: CPAP treatment versus control group.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint: Change in arterial stiffness measured by office carotid-femoral pulse wave&#xD;
      velocity (cf-PWV) from start to end of 12 weeks intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention</measure>
    <time_frame>three month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from start to end of 13 weeks intervention in insulin sensitivity measured by hyperinsulinemic euglycemic clamp</measure>
    <time_frame>three month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetes</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous Positive Airway Pressure (CPAP) treatment during three month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP intervention</description>
    <arm_group_label>CPAP treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus (WHO criteria)&#xD;
&#xD;
          -  Obstructive sleep apnea defined as apnoea-hypopnoea index (AHI) &gt; 15 diagnosed with&#xD;
             ApneaLink+® measured within three months or less prior to visit 0.&#xD;
&#xD;
          -  Signed informed content.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to CPAP treatment.&#xD;
&#xD;
          -  Treatment with CPAP within the last 6 months prior to visit 1.&#xD;
&#xD;
          -  Works in a transportation-related industry&#xD;
&#xD;
          -  C-peptide &lt; 300 pmol/l - measured less than 6 months prior to visit 0&#xD;
&#xD;
          -  HbA1c:&lt; 7% or &gt;10% - both exclusive - at visit 0&#xD;
&#xD;
          -  Changes in antidiabetic treatment during the last four weeks prior to visit 0.&#xD;
&#xD;
          -  Unstable bodyweight, i.e. &gt;5% change during the last three months prior to visit 0.&#xD;
&#xD;
          -  Other sleep breathing disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esben Laugesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus Universitets Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Banghøj, MD</last_name>
    <email>anne.margareta.banghoej@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nordsjællands hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Banghøj, MD</last_name>
      <email>anne.margareta.banghoej@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

